Market Place
Sourcing Support
Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA
29 Nov 2023 //
BUSINESSWIRE
Kyowa Kirin brings rare disease drug`s marketing back in house, future US growth
03 May 2023 //
ENDPTS
Ultragenyx Announces Sale of Portion of Future N. American Royalties on Crysvita
14 Jul 2022 //
GLOBENEWSWIRE
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for TIO
24 Jun 2022 //
BUSINESSWIRE
Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data
27 Sep 2021 //
GLOBENEWSWIRE
New data demonstrates long-term benefit of Crysvita for XLH patients
25 Sep 2021 //
PHARMATIMES
Crysvita treatment reduces burden of disease in adults
24 Sep 2021 //
BUSINESSWIRE
Health Canada approves Ultragenyx`s second indication for Crysvita
07 Sep 2021 //
GLOBENEWSWIRE
Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population
05 Oct 2020 //
PHARMATIMES
Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population
05 Oct 2020 //
PHARMATIMES
Kyowa Kirin Announces European Commission (EC) Approval of CRYSVITA®
02 Oct 2020 //
BUSINESSWIRE
CHMP backs expanding scope of Kyowa Kirin`s Crysvita
27 Jul 2020 //
PHARMATIMES
Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA®
24 Jul 2020 //
BUSINESSWIRE
Ultragenyx`s Crysvita (Burosumab- twza) Receives Supplemental Approval in US
26 Jun 2020 //
FDA
FDA Approvals Roundup: Tazverik, Crysvita, Xpovio
24 Jun 2020 //
RAPS
FDA Approves Therapy for Rare Disease that Causes Low Phosphate Blood Levels
18 Jun 2020 //
PR NEWSWIRE
Scottish Medicines Consortium enables access to treatment for rare inherited
18 Feb 2020 //
PHARMAFILE
Ultragenyx`s Crysvita (Burosumab twza) Receives Supplemental Approval in US
30 Sep 2019 //
FDA
XLH patients to get routine access to first new therapy in 30 years
10 Oct 2018 //
PHARMA TIMES
NICE u-turn approves funding for rare disease therapy Crysvita
05 Sep 2018 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.